Jihyun Jang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jihyun Jang has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Deqiang Li
Center for Cardiovascular Research, Abigail Wexner Research Institute, Nationwide Children’s Hospital, Columbus, USA
8 shared publications Qinshan Li
Center for Vascular and Inflammation Diseases (J.J., G.S., S.M.P., Q.L., X.S., D.L.), University of Maryland School of Medicine, Baltimore‚ MD
2 shared publications- Sung Joon Kim
Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea
2 shared publications Sunjay Kaushal
Division of Cardiovascular-Thoracic Surgery, Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago‚ IL (S.K.).
2 shared publications- Vidu Garg
Department of Pediatrics The Ohio State University College of Medicine Columbus Ohio USA
2 shared publications Xiaosu Song
Center for Vascular and Inflammation Diseases (J.J., G.S., S.M.P., Q.L., X.S., D.L.), University of Maryland School of Medicine, Baltimore‚ MD
2 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Rockefeller University Press in Journal of General Physiology
- Vol. 158 (6)
Chamber-specific regulation of myofilament Ca2+ sensitivity by nNOSβ via troponin I phosphorylation: Predominance in the right ventricle
Neuronal nitric oxide (NO) synthase (nNOS) is an important regulator of excitation–contraction coupling in cardiomyocytes, yet its chamber-specific role in right ventricular cardiomyocytes (RVCMs) remains incompletely understood. In this study, we compared the effects of nNOS inhibition on contractile function, Ca2+ signaling, and myofilament-associated regulation in RVCMs and left ventricular cardiomyocytes (LVCMs). Pharmacological inhibition of nNOS with S-methyl-L-thiocitrulline (SMTC) enhanced sarcomere shortening and impaired relaxation in both cell types, with markedly greater effects observed in RVCMs. In contrast, SMTC-induced changes in Ca2+ transients and L-type Ca2+ current were more pronounced in LVCMs than in RVCMs, indicating a dissociation between Ca2+ signaling and mechanical responses in the SMTC-treated RVCMs. Analysis of dynamic Ca2+-sarcomere length coupling indicated that nNOS inhibition in RVCMs preferentially altered the relationship between intracellular Ca2+ signaling and sarcomere response, particularly during relaxation, rather than simply reflecting changes in Ca2+ magnitude. Consistent with this interpretation, inhibition of nNOS reduced cardiac troponin I (cTnI) Ser23/24 phosphorylation and was associated with altered endogenous Ca2+ buffering properties in RVCMs. Moreover, myofilament-enriched fractions from RVCMs exhibited higher levels of Ser1417-phosphorylated nNOSβ. Collectively, these data indicate that myofilament-associated nNOSβ predominantly regulates RV contractility through cTnI phosphorylation-mediated Ca2+ desensitization.
- 5 October 2026
- Published by Rockefeller University Press in Journal of General Physiology
- Vol. 158 (6)
Open AccessChamber-specific regulation of myofilament Ca2+ sensitivity by nNOSβ via troponin I phosphorylation: Predominance in the right ventricle
Neuronal nitric oxide (NO) synthase (nNOS) is an important regulator of excitation–contraction coupling in cardiomyocytes, yet its chamber-specific role in right ventricular cardiomyocytes (RVCMs) remains incompletely understood. In this study, we compared the effects of nNOS inhibition on contractile function, Ca2+ signaling, and myofilament-associated regulation in RVCMs and left ventricular cardiomyocytes (LVCMs). Pharmacological inhibition of nNOS with S-methyl-L-thiocitrulline (SMTC) enhanced sarcomere shortening and impaired relaxation in both cell types, with markedly greater effects observed in RVCMs. In contrast, SMTC-induced changes in Ca2+ transients and L-type Ca2+ current were more pronounced in LVCMs than in RVCMs, indicating a dissociation between Ca2+ signaling and mechanical responses in the SMTC-treated RVCMs. Analysis of dynamic Ca2+-sarcomere length coupling indicated that nNOS inhibition in RVCMs preferentially altered the relationship between intracellular Ca2+ signaling and sarcomere response, particularly during relaxation, rather than simply reflecting changes in Ca2+ magnitude. Consistent with this interpretation, inhibition of nNOS reduced cardiac troponin I (cTnI) Ser23/24 phosphorylation and was associated with altered endogenous Ca2+ buffering properties in RVCMs. Moreover, myofilament-enriched fractions from RVCMs exhibited higher levels of Ser1417-phosphorylated nNOSβ. Collectively, these data indicate that myofilament-associated nNOSβ predominantly regulates RV contractility through cTnI phosphorylation-mediated Ca2+ desensitization.
- Open Access
- 1 September 2025
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 57 (9) , 1893-1901
m6A and cardiac posttranscriptional regulation: a novel player in heart development and disease
The growing body of research on cardiac epitranscriptomic factors has underscored their potential biological roles and impact on heart development and disease. While transcriptional and translational regulation of cardiac genes in the developing heart has been extensively studied, the potential roles of posttranscriptional regulation of cardiac mRNAs remain a significant gap in our understanding. In addition, discrepancies between transcriptomes and proteomes in both embryonic and adult hearts are well recognized, further suggesting an emerging regulatory role of the epitranscriptome in cardiac biology. Here we summarize the current understanding of m6A machinery and associated RNA-binding proteins in the heart and discuss their impact on heart development. By identifying existing knowledge gaps, we aim to provide insights that may inform future research directions.
- 1 September 2025
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 57 (9) , 1893-1901
Open Accessm6A and cardiac posttranscriptional regulation: a novel player in heart development and disease
The growing body of research on cardiac epitranscriptomic factors has underscored their potential biological roles and impact on heart development and disease. While transcriptional and translational regulation of cardiac genes in the developing heart has been extensively studied, the potential roles of posttranscriptional regulation of cardiac mRNAs remain a significant gap in our understanding. In addition, discrepancies between transcriptomes and proteomes in both embryonic and adult hearts are well recognized, further suggesting an emerging regulatory role of the epitranscriptome in cardiac biology. Here we summarize the current understanding of m6A machinery and associated RNA-binding proteins in the heart and discuss their impact on heart development. By identifying existing knowledge gaps, we aim to provide insights that may inform future research directions.
- Open Access
- 26 August 2025
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 208, 11-22
Regulation of atrial and ventricular cardiomyocyte identity
- 26 August 2025
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 208, 11-22
Open AccessRegulation of atrial and ventricular cardiomyocyte identity
- 10 June 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (23) , 1692-1695
Loss of Methyltransferase and Hypomethylated m6A Sarcomere Transcripts Leading to Early-Onset Dilated Cardiomyopathy
- 10 June 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (23) , 1692-1695
Loss of Methyltransferase and Hypomethylated m6A Sarcomere Transcripts Leading to Early-Onset Dilated Cardiomyopathy
- Open Access
- 16 May 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-12
Endocardial HDAC3 is required for myocardial trabeculation
Failure of proper ventricular trabeculation is often associated with congenital heart disease. Support from endocardial cells, including the secretion of extracellular matrix and growth factors is critical for trabeculation. However, it is poorly understood how the secretion of extracellular matrix and growth factors is initiated and regulated by endocardial cells. We find that genetic knockout of histone deacetylase 3 in the endocardium in mice results in early embryo lethality and ventricular hypotrabeculation. Single cell RNA sequencing identifies significant downregulation of extracellular matrix components in histone deacetylase 3 knockout endocardial cells. Secretome from cultured histone deacetylase 3 knockout mouse cardiac endothelial cells lacks transforming growth factor ß3 and shows significantly reduced capacity in stimulating cultured cardiomyocyte proliferation, which is remarkably rescued by transforming growth factor ß3 supplementation. Mechanistically, we identify that histone deacetylase 3 knockout induces transforming growth factor ß3 expression through repressing microRNA-129-5p. Our findings provide insights into the pathogenesis of congenital heart disease and conceptual strategies to promote myocardial regeneration.
- 16 May 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-12
Open AccessEndocardial HDAC3 is required for myocardial trabeculation
Failure of proper ventricular trabeculation is often associated with congenital heart disease. Support from endocardial cells, including the secretion of extracellular matrix and growth factors is critical for trabeculation. However, it is poorly understood how the secretion of extracellular matrix and growth factors is initiated and regulated by endocardial cells. We find that genetic knockout of histone deacetylase 3 in the endocardium in mice results in early embryo lethality and ventricular hypotrabeculation. Single cell RNA sequencing identifies significant downregulation of extracellular matrix components in histone deacetylase 3 knockout endocardial cells. Secretome from cultured histone deacetylase 3 knockout mouse cardiac endothelial cells lacks transforming growth factor ß3 and shows significantly reduced capacity in stimulating cultured cardiomyocyte proliferation, which is remarkably rescued by transforming growth factor ß3 supplementation. Mechanistically, we identify that histone deacetylase 3 knockout induces transforming growth factor ß3 expression through repressing microRNA-129-5p. Our findings provide insights into the pathogenesis of congenital heart disease and conceptual strategies to promote myocardial regeneration.
- 26 March 2024
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 257, 108638
Epigenetic determinants and non-myocardial signaling pathways contributing to heart growth and regeneration
- 26 March 2024
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 257, 108638
Epigenetic determinants and non-myocardial signaling pathways contributing to heart growth and regeneration
- Open Access
- 1 January 2023
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 13 (17) , e4802
Isolation of Embryonic Cardiomyocytes and Cell Proliferation Assay Using Genetically Engineered Reporter Mouse Model
Congenital heart disease (CHD) is often associated with myogenic defects. During heart development, cardiomyocyte growth requires essential cues from extrinsic factors such as insulin-like growth factor 2 (IGF-2). To determine whether and how growth factors account for embryonic cardiomyocyte proliferation, isolation followed by culturing of embryonic cardiomyocytes can be utilized as a useful tool for heart developmental studies. Current protocols for isolating cardiomyocytes from the heart do not include a cardiomyocyte-specific reporter to distinguish cardiomyocytes from other cell types. To optimize visualization of cardiomyocyte proliferation, our protocol utilizes a Tnnt2-promoter-driven H2B-GFP knock-in mouse model (TNNT2H2B-GFP/+) for in vitro visualization of nuclear-tagged cardiomyocyte-specific fluorescence. A cardiomyocyte-specific genetic reporter paired with an effective proliferation assay improves the reproducibility of mechanistic studies by increasing the accuracy of cell identification, proliferated cell counting, and cardiomyocyte tracking.
- 1 January 2023
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 13 (17) , e4802
Open AccessIsolation of Embryonic Cardiomyocytes and Cell Proliferation Assay Using Genetically Engineered Reporter Mouse Model
Congenital heart disease (CHD) is often associated with myogenic defects. During heart development, cardiomyocyte growth requires essential cues from extrinsic factors such as insulin-like growth factor 2 (IGF-2). To determine whether and how growth factors account for embryonic cardiomyocyte proliferation, isolation followed by culturing of embryonic cardiomyocytes can be utilized as a useful tool for heart developmental studies. Current protocols for isolating cardiomyocytes from the heart do not include a cardiomyocyte-specific reporter to distinguish cardiomyocytes from other cell types. To optimize visualization of cardiomyocyte proliferation, our protocol utilizes a Tnnt2-promoter-driven H2B-GFP knock-in mouse model (TNNT2H2B-GFP/+) for in vitro visualization of nuclear-tagged cardiomyocyte-specific fluorescence. A cardiomyocyte-specific genetic reporter paired with an effective proliferation assay improves the reproducibility of mechanistic studies by increasing the accuracy of cell identification, proliferated cell counting, and cardiomyocyte tracking.
- 8 July 2022
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 131 (2) , 151-164
Epicardial HDAC3 Promotes Myocardial Growth Through a Novel MicroRNA Pathway
Background: Establishment of the myocardial wall requires proper growth cues from nonmyocardial tissues. During heart development, the epicardium and epicardium-derived cells instruct myocardial growth by secreting essential factors including FGF (fibroblast growth factor) 9 and IGF (insulin-like growth factor) 2. However, it is poorly understood how the epicardial secreted factors are regulated, in particular by chromatin modifications for myocardial formation. The current study is to investigate whether and how HDAC (histone deacetylase) 3 in the developing epicardium regulates myocardial growth. Methods: Various cellular and mouse models in conjunction with biochemical and molecular tools were employed to study the role of HDAC3 in the developing epicardium. Results: We deleted Hdac3 in the developing murine epicardium, and mutant hearts showed ventricular myocardial wall hypoplasia with reduction of epicardium-derived cells. The cultured embryonic cardiomyocytes with supernatants from Hdac3 knockout (KO) mouse epicardial cells also showed decreased proliferation. Genome-wide transcriptomic analysis revealed that Fgf9 and Igf2 were significantly downregulated in Hdac3 KO mouse epicardial cells. We further found that Fgf9 and Igf2 expression is dependent on HDAC3 deacetylase activity. The supplementation of FGF9 or IGF2 can rescue the myocardial proliferation defects treated by Hdac3 KO supernatant. Mechanistically, we identified that microRNA (miR)-322 and miR-503 were upregulated in Hdac3 KO mouse epicardial cells and Hdac3 epicardial KO hearts. Overexpression of miR-322 or miR-503 repressed FGF9 and IGF2 expression, while knockdown of miR-322 or miR-503 restored FGF9 and IGF2 expression in Hdac3 KO mouse epicardial cells. Conclusions: Our findings reveal a critical signaling pathway in which epicardial HDAC3 promotes compact myocardial growth by stimulating FGF9 and IGF2 through repressing miR-322 or miR-503, providing novel insights in elucidating the etiology of congenital heart defects and conceptual strategies to promote myocardial regeneration.
- 8 July 2022
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 131 (2) , 151-164
Epicardial HDAC3 Promotes Myocardial Growth Through a Novel MicroRNA Pathway
Background: Establishment of the myocardial wall requires proper growth cues from nonmyocardial tissues. During heart development, the epicardium and epicardium-derived cells instruct myocardial growth by secreting essential factors including FGF (fibroblast growth factor) 9 and IGF (insulin-like growth factor) 2. However, it is poorly understood how the epicardial secreted factors are regulated, in particular by chromatin modifications for myocardial formation. The current study is to investigate whether and how HDAC (histone deacetylase) 3 in the developing epicardium regulates myocardial growth. Methods: Various cellular and mouse models in conjunction with biochemical and molecular tools were employed to study the role of HDAC3 in the developing epicardium. Results: We deleted Hdac3 in the developing murine epicardium, and mutant hearts showed ventricular myocardial wall hypoplasia with reduction of epicardium-derived cells. The cultured embryonic cardiomyocytes with supernatants from Hdac3 knockout (KO) mouse epicardial cells also showed decreased proliferation. Genome-wide transcriptomic analysis revealed that Fgf9 and Igf2 were significantly downregulated in Hdac3 KO mouse epicardial cells. We further found that Fgf9 and Igf2 expression is dependent on HDAC3 deacetylase activity. The supplementation of FGF9 or IGF2 can rescue the myocardial proliferation defects treated by Hdac3 KO supernatant. Mechanistically, we identified that microRNA (miR)-322 and miR-503 were upregulated in Hdac3 KO mouse epicardial cells and Hdac3 epicardial KO hearts. Overexpression of miR-322 or miR-503 repressed FGF9 and IGF2 expression, while knockdown of miR-322 or miR-503 restored FGF9 and IGF2 expression in Hdac3 KO mouse epicardial cells. Conclusions: Our findings reveal a critical signaling pathway in which epicardial HDAC3 promotes compact myocardial growth by stimulating FGF9 and IGF2 through repressing miR-322 or miR-503, providing novel insights in elucidating the etiology of congenital heart defects and conceptual strategies to promote myocardial regeneration.
- Open Access
- 31 January 2022
- Published by Rockefeller University Press in Journal of General Physiology
- Vol. 154 (3)
Lower troponin expression in the right ventricle of rats explains interventricular differences in E–C coupling
Despite distinctive functional and anatomic differences, a precise understanding of the cardiac interventricular differences in excitation–contraction (E–C) coupling mechanisms is still lacking. Here, we directly compared rat right and left cardiomyocytes (RVCM and LVCM). Whole-cell patch clamp, the IonOptix system, and fura-2 fluorimetry were used to measure electrical properties (action potential and ionic currents), single-cell contractility, and cytosolic Ca2+ ([Ca2+]i), respectively. Myofilament proteins were analyzed by immunoblotting. RVCM showed significantly shorter action potential duration (APD) and higher density of transient outward K+ current (Ito). However, the triggered [Ca2+]i change (Ca2+ transient) was not different, while the decay rate of the Ca2+ transient was slower in RVCM. Although the relaxation speed was also slower, the sarcomere shortening amplitude (ΔSL) was smaller in RVCM. SERCA activity was ∼60% lower in RVCM, which is partly responsible for the slower decay of the Ca2+ transient. Immunoblot analysis revealed lower expression of the cardiac troponin complex (cTn) in RVCM, implying a smaller Ca2+ buffering capacity (κS), which was proved by in situ analysis. The introduction of these new levels of cTn, Ito, and SERCA into a mathematical model of rat LVCM reproduced the similar Ca2+ transient, slower Ca2+ decay, shorter APD, and smaller ΔSL of RVCM. Taken together, these data show reduced expression of cTn proteins in the RVCM, which provides an explanation for the interventricular difference in the E–C coupling kinetics.
- 31 January 2022
- Published by Rockefeller University Press in Journal of General Physiology
- Vol. 154 (3)
Open AccessLower troponin expression in the right ventricle of rats explains interventricular differences in E–C coupling
Despite distinctive functional and anatomic differences, a precise understanding of the cardiac interventricular differences in excitation–contraction (E–C) coupling mechanisms is still lacking. Here, we directly compared rat right and left cardiomyocytes (RVCM and LVCM). Whole-cell patch clamp, the IonOptix system, and fura-2 fluorimetry were used to measure electrical properties (action potential and ionic currents), single-cell contractility, and cytosolic Ca2+ ([Ca2+]i), respectively. Myofilament proteins were analyzed by immunoblotting. RVCM showed significantly shorter action potential duration (APD) and higher density of transient outward K+ current (Ito). However, the triggered [Ca2+]i change (Ca2+ transient) was not different, while the decay rate of the Ca2+ transient was slower in RVCM. Although the relaxation speed was also slower, the sarcomere shortening amplitude (ΔSL) was smaller in RVCM. SERCA activity was ∼60% lower in RVCM, which is partly responsible for the slower decay of the Ca2+ transient. Immunoblot analysis revealed lower expression of the cardiac troponin complex (cTn) in RVCM, implying a smaller Ca2+ buffering capacity (κS), which was proved by in situ analysis. The introduction of these new levels of cTn, Ito, and SERCA into a mathematical model of rat LVCM reproduced the similar Ca2+ transient, slower Ca2+ decay, shorter APD, and smaller ΔSL of RVCM. Taken together, these data show reduced expression of cTn proteins in the RVCM, which provides an explanation for the interventricular difference in the E–C coupling kinetics.
- Open Access
Epicardial HDAC3 promotes myocardial growth through a novel microRNA pathway
Rational: Establishment of the myocardial wall requires proper growth cues from nonmyocardial tissues. During heart development, the epicardium and epicardium-derived cells (EPDCs) instruct myocardial growth by secreting essential factors including fibroblast growth factor 9 (FGF9) and insulin-like growth factor 2 (IGF2). However, it is poorly understood how the epicardial secreted factors are regulated, in particular by chromatin modifications for myocardial formation. Objective: To understand whether and how histone deacetylase 3 (HDAC3) in the developing epicardium regulates myocardial growth. Methods and Results: We deleted Hdac3 in the developing murine epicardium and mutant hearts showed ventricular myocardial wall hypoplasia with reduction of EPDCs. The cultured embryonic cardiomyocytes with supernatants from Hdac3 knockout (KO) mouse epicardial cells (MECs) also showed decreased proliferation. Genome-wide transcriptomic analysis revealed that Fgf9 and Igf2 were significantly down-regulated in Hdac3 KO MECs. We further found that Fgf9 and Igf2 expression is dependent on HDAC3 deacetylase activity. The supplementation of FGF9 or IGF2 can rescue the myocardial proliferation defects treated by Hdac3 KO supernatant. Mechanistically, we identified that microRNA (miR)-322 and miR-503 were upregulated in Hdac3 KO MECs and Hdac3 epicardial KO hearts. Overexpression of miR-322 or miR-503 repressed FGF9 and IGF2 expression, while knockdown of miR-322 or miR-503 restored FGF9 and IGF2 expression in Hdac3 KO MECs. Conclusions: Our findings reveal a critical signaling pathway in which epicardial HDAC3 promotes compact myocardial growth by stimulating FGF9 and IGF2 through repressing miR-322/miR-503, providing novel insights in elucidating etiology of congenital heart defects, and conceptual strategies to promote myocardial regeneration.
Open AccessEpicardial HDAC3 promotes myocardial growth through a novel microRNA pathway
Rational: Establishment of the myocardial wall requires proper growth cues from nonmyocardial tissues. During heart development, the epicardium and epicardium-derived cells (EPDCs) instruct myocardial growth by secreting essential factors including fibroblast growth factor 9 (FGF9) and insulin-like growth factor 2 (IGF2). However, it is poorly understood how the epicardial secreted factors are regulated, in particular by chromatin modifications for myocardial formation. Objective: To understand whether and how histone deacetylase 3 (HDAC3) in the developing epicardium regulates myocardial growth. Methods and Results: We deleted Hdac3 in the developing murine epicardium and mutant hearts showed ventricular myocardial wall hypoplasia with reduction of EPDCs. The cultured embryonic cardiomyocytes with supernatants from Hdac3 knockout (KO) mouse epicardial cells (MECs) also showed decreased proliferation. Genome-wide transcriptomic analysis revealed that Fgf9 and Igf2 were significantly down-regulated in Hdac3 KO MECs. We further found that Fgf9 and Igf2 expression is dependent on HDAC3 deacetylase activity. The supplementation of FGF9 or IGF2 can rescue the myocardial proliferation defects treated by Hdac3 KO supernatant. Mechanistically, we identified that microRNA (miR)-322 and miR-503 were upregulated in Hdac3 KO MECs and Hdac3 epicardial KO hearts. Overexpression of miR-322 or miR-503 repressed FGF9 and IGF2 expression, while knockdown of miR-322 or miR-503 restored FGF9 and IGF2 expression in Hdac3 KO MECs. Conclusions: Our findings reveal a critical signaling pathway in which epicardial HDAC3 promotes compact myocardial growth by stimulating FGF9 and IGF2 through repressing miR-322/miR-503, providing novel insights in elucidating etiology of congenital heart defects, and conceptual strategies to promote myocardial regeneration.